ITF Therapeutics LLC
Ed Hrubiec is a seasoned professional in the pharmaceutical and biotechnology industries, currently serving as the Regional Business Director for the Northeast at ITF Therapeutics LLC, specializing in pediatric neuromuscular rare diseases. Previous roles include Regional Access Manager and Regional Business Director at Amylyx Pharmaceuticals, where responsibilities encompassed market access and sales leadership for rare diseases. Ed's extensive experience includes positions at Intercept Pharmaceuticals, AbbVie, Vertex Pharmaceuticals, Gilead Sciences, and Abbott, focusing on access management, specialty sales, and key account management across various therapeutic areas. Ed holds a Bachelor of Science in Applied Professional Sciences with a minor in Business Marketing from the University of South Carolina.
This person is not in the org chart
This person is not in any teams
ITF Therapeutics LLC
ITF Therapeutics is the U.S.-based rare disease division of Italfarmaco S.p.A. Founded in 1938 in Milan, Italy, Italfarmaco is a private global pharmaceutical company that has led the successful development of many innovative therapeutic products approved for use by patients around the world. The company operates in more than 60 countries on five continents and continues to advance promising research to address unmet medical needs in a wide range of therapeutic areas. In January 2024, Italfarmaco launched ITF Therapeutics as a new division in the United States with a focus on the development and commercialization of products to treat rare diseases including Duchenne muscular dystrophy (DMD). Building on a legacy grounded in collaboration and innovation, ITF Therapeutics strives to partner with leaders from the U.S. patient advocacy and treatment communities to ensure that our programs reflect and support their unique needs and goals. The establishment of ITF Therapeutics also reflects Italfarmaco’s goal to build a world-class team of experts that share a passion to make a positive impact for rare disease communities.